Clinical trials
Cancer Pain trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 7 |
| Unknown status | 7 |
| Not yet recruiting | 4 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fujian Cancer Hospital | 3 |
| Fuda Cancer Hospital, Guangzhou | 2 |
| Henan Cancer Hospital | 2 |
| Mundipharma (China) Pharmaceutical Co. Ltd | 2 |
| Zhejiang Cancer Hospital | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Chongqing University Cancer Hospital | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Nakhia Impex LLC | 1 |
| Pfizer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cancer Pain | 29 |
| Pain | 5 |
| Neoplasms | 3 |
| Agnosia | 1 |
| Carcinoma | 1 |
| Carcinoma, Hepatocellular | 1 |
| Colorectal Neoplasms | 1 |
| Liver Neoplasms | 1 |
| Lymphoma, Follicular | 1 |
| Multiple Myeloma | 1 |
Trials
Showing 76 to 29 of 29. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.